Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
diagnoSwiss is a Swiss biotechnology company specializing in the development of advanced microfluidic systems and proteomic analysis tools. The company is best known for its proprietary OFFGEL electrophoresis technology, which allows for the pI-based fractionation of proteins and peptides in a liquid phase, significantly improving the efficiency of mass spectrometry workflows. Their products focus on simplifying complex biological sample preparation for research and clinical diagnostics. By integrating micro-engineering with analytical chemistry, diagnoSwiss provides high-resolution separation solutions that are widely utilized in top-down and bottom-up proteomics.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on diagnoSwiss.